Literature DB >> 20883474

Teneurin C-terminal associated peptide-1 blocks the effects of corticotropin-releasing factor on reinstatement of cocaine seeking and on cocaine-induced behavioural sensitization.

David A Kupferschmidt1, David A Lovejoy, Susan Rotzinger, Suzanne Erb.   

Abstract

BACKGROUND AND
PURPOSE: The stress-related neuropeptide, corticotropin-releasing factor (CRF), has become an important focus of studies of cocaine addiction, and in particular, the effects of stress on cocaine-related behaviours. A recently discovered peptide system, the teneurin C-terminal associated peptides (TCAP), has been implicated in the regulation of the stress response, via a CRF-related mechanism. Here we have determined whether treatment with TCAP-1, a synthetic analogue of TCAP, modulated two cocaine-related behaviours induced by CRF: reinstatement of cocaine seeking, and expression of cocaine-induced behavioural sensitization. EXPERIMENTAL APPROACH: In Experiment 1, rats trained to self-administer cocaine were given acute or repeated (once daily for 5 days) i.c.v. injections of TCAP-1 before tests for reinstatement in response to CRF (105 pmol, i.c.v.), intermittent footshock stress (0.9 mA), or cocaine (15 mg·kg⁻¹, i.p.). In Experiment 2, rats pre-exposed to cocaine (15-30 mg·kg⁻¹, i.p.) or saline for 7 days were treated with TCAP-1 (once daily for 5 days; i.c.v.) and subsequently tested for locomotor responses to CRF (105 pmol, i.c.v.) or cocaine (15 mg·kg⁻¹, i.p.). KEY
RESULTS: Five day pre-exposure with TCAP-1 blocked CRF-, but not footshock- or cocaine-induced reinstatement of cocaine seeking; acute pretreatment with TCAP-1 was without effect in all test conditions. Similarly, repeated TCAP-1 pre-exposure blocked the cocaine-sensitized locomotor response to CRF, but not to cocaine. CONCLUSIONS AND IMPLICATIONS: Repeated TCAP-1 exposure induced robust and selective inhibition of cocaine-related behavioural responses to CRF, suggesting that TCAP-1 may normalize signalling within CRF systems dysregulated by cocaine exposure.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20883474      PMCID: PMC3041248          DOI: 10.1111/j.1476-5381.2010.01055.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  49 in total

1.  Repeated cocaine alters glutamate receptor subunit levels in the nucleus accumbens and ventral tegmental area of rats that develop behavioral sensitization.

Authors:  L Churchill; C J Swanson; M Urbina; P W Kalivas
Journal:  J Neurochem       Date:  1999-06       Impact factor: 5.372

Review 2.  Teneurin C-terminal associated peptides: an enigmatic family of neuropeptides with structural similarity to the corticotropin-releasing factor and calcitonin families of peptides.

Authors:  David A Lovejoy; Arij Al Chawaf; M Z Alia Cadinouche
Journal:  Gen Comp Endocrinol       Date:  2006-03-09       Impact factor: 2.822

3.  Cocaine self-administration increases the incentive motivational properties of the drug in rats.

Authors:  V Deroche; M Le Moal; P V Piazza
Journal:  Eur J Neurosci       Date:  1999-08       Impact factor: 3.386

4.  Effects of CP 154,526, a CRF1 receptor antagonist, on behavioral responses to cocaine in rats.

Authors:  Edmund Przegaliński; Małgorzata Filip; Małgorzata Frankowska; Magdalena Zaniewska; Iwona Papla
Journal:  Neuropeptides       Date:  2005-09-02       Impact factor: 3.286

5.  Cocaine pre-exposure enhances CRF-induced expression of c-fos mRNA in the central nucleus of the amygdala: an effect that parallels the effects of cocaine pre-exposure on CRF-induced locomotor activity.

Authors:  Suzanne Erb; Douglas Funk; Anh Dzung Lê
Journal:  Neurosci Lett       Date:  2005-04-26       Impact factor: 3.046

6.  Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists.

Authors:  Lotte de Groote; Rosana G Peñalva; Cornelia Flachskamm; Johannes M H M Reul; Astrid C E Linthorst
Journal:  J Neurochem       Date:  2005-07       Impact factor: 5.372

7.  A role for corticotropin-releasing factor in the long-term expression of behavioral sensitization to cocaine.

Authors:  Suzanne Erb; Zenya J Brown
Journal:  Behav Brain Res       Date:  2006-07-05       Impact factor: 3.332

8.  Cocaine experience establishes control of midbrain glutamate and dopamine by corticotropin-releasing factor: a role in stress-induced relapse to drug seeking.

Authors:  Bin Wang; Yavin Shaham; Dawnya Zitzman; Soraya Azari; Roy A Wise; Zhi-Bing You
Journal:  J Neurosci       Date:  2005-06-01       Impact factor: 6.167

9.  Central injections of CRF reinstate cocaine seeking in rats after postinjection delays of up to 3 h: an influence of time and environmental context.

Authors:  Suzanne Erb; Ana Petrovic; Daniel Yi; Hanan Kayyali
Journal:  Psychopharmacology (Berl)       Date:  2006-05-03       Impact factor: 4.530

Review 10.  Teneurins: a conserved family of transmembrane proteins involved in intercellular signaling during development.

Authors:  R P Tucker; R Chiquet-Ehrismann
Journal:  Dev Biol       Date:  2006-01-09       Impact factor: 3.582

View more
  9 in total

1.  Cannabinoid CB1 receptors mediate the effects of corticotropin-releasing factor on the reinstatement of cocaine seeking and expression of cocaine-induced behavioural sensitization.

Authors:  D A Kupferschmidt; P G Klas; S Erb
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Reinstatement of cocaine seeking in rats by the pharmacological stressors, corticotropin-releasing factor and yohimbine: role for D1/5 dopamine receptors.

Authors:  Z J Brown; D A Kupferschmidt; Suzanne Erb
Journal:  Psychopharmacology (Berl)       Date:  2012-06-17       Impact factor: 4.530

Review 3.  Corticotropin releasing factor: a key role in the neurobiology of addiction.

Authors:  Eric P Zorrilla; Marian L Logrip; George F Koob
Journal:  Front Neuroendocrinol       Date:  2014-01-20       Impact factor: 8.606

4.  Teneurin and TCAP Phylogeny and Physiology: Molecular Analysis, Immune Activity, and Transcriptomic Analysis of the Stress Response in the Sydney Rock Oyster (Saccostrea glomerata) Hemocytes.

Authors:  Tomer Abramov; Saowaros Suwansa-Ard; Patricia Mirella da Silva; Tianfang Wang; Michael Dove; Wayne O'Connor; Laura Parker; David A Lovejoy; Scott F Cummins; Abigail Elizur
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

Review 5.  Ancient interaction between the teneurin C-terminal associated peptides (TCAP) and latrophilin ligand-receptor coupling: a role in behavior.

Authors:  Rebecca Woelfle; Andrea L D'Aquila; Téa Pavlović; Mia Husić; David A Lovejoy
Journal:  Front Neurosci       Date:  2015-04-24       Impact factor: 4.677

Review 6.  Teneurins, TCAP, and latrophilins: roles in the etiology of mood disorders.

Authors:  Rebecca Woelfle; Andrea L D'Aquila; David A Lovejoy
Journal:  Transl Neurosci       Date:  2016-02-24       Impact factor: 1.757

Review 7.  Activity of the Carboxy-Terminal Peptide Region of the Teneurins and Its Role in Neuronal Function and Behavior in Mammals.

Authors:  David W Hogg; Mia Husić; David Wosnick; Thomas Dodsworth; Andrea L D'Aquila; David A Lovejoy
Journal:  Front Neurosci       Date:  2019-07-31       Impact factor: 4.677

Review 8.  Teneurin C-terminal associated peptides (TCAP): modulators of corticotropin-releasing factor (CRF) physiology and behavior.

Authors:  Yani Chen; Mei Xu; Reuben De Almeida; David A Lovejoy
Journal:  Front Neurosci       Date:  2013-09-17       Impact factor: 4.677

9.  Synthetic Peptides as Therapeutic Agents: Lessons Learned From Evolutionary Ancient Peptides and Their Transit Across Blood-Brain Barriers.

Authors:  David A Lovejoy; David W Hogg; Thomas L Dodsworth; Fernando R Jurado; Casey C Read; Andrea L D'Aquila; Dalia Barsyte-Lovejoy
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-12       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.